GABAAalpha5 receptor modulation for the treatment of Dup15q syndrome: the QUINDECIM study

Time: 4:00 pm


  • The Quindecim phase 2 pediatric study in Dup15q syndrome is the first to target proximal disease mechanisms.
  • Exploring the hypothesis that basmisanil, a selective and potent GABAAalpha5 NAM, can correct excess GABAA receptor function and improve functional outcomes in Dup15q syndrome.
  • Implementing a precision medicine approach, leveraging a translational qEEG biomarker of GABAA receptor function, uniquely positioned to assess the pharmacodynamic effect of basmisanil on the GABAA-related disease pathology and its relationship to (potential) clinical benefit.